BioSpace News Archive

Merck, known as MSD outside the United States and Canada, issued its 2021/2022 Environmental, Social and Governance Progress Report.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2022 at 11:55am PT / 2:55pm ET.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Morgan Stanley 20th Annual Global Healthcare Conference.

Lyell Immunopharma, Inc., a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that members of its senior management team will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, at 1:05 p.m. ET.

San Jose BioCube, a leading life-sciences incubator, announced the opening of “BioCube North” at 2680 Zanker Road in North San Jose, California.

In a video interview on “Hot Topics in Emergency Medicine” posted by Medscape, a group of emergency medicine experts and respiratory physiology thought leaders discussed a new non-invasive measurement; Oxygen Deficit, obtained from the MediPines AGM100, which demonstrated 99% clinical accuracy for supplemental oxygen therapy decisions.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Disease-modifying antirheumatic drugs (DMARDs) are a class of drugs utilized as a therapy for inflammatory arthritis, including psoriatic arthritis (PsA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS).

DW Healthcare Partners (“DWHP”) a healthcare-focused private equity firm, announced the closing of its sale of Med-Pharmex Holdings, Inc (“Med-Pharmex”, or the “Company”) to Dechra Pharmaceuticals PLC (“Dechra”). Med-Pharmex is a leading, fully-integrated veterinary pharmaceutical manufacturer focused on developing, manufacturing, and commercializing animal health drugs.

The U.S. Food and Drug Administration has accepted for priority review the Biologics License Application for efanesoctocog alfa for the treatment of hemophilia A, a rare and life-threatening bleeding disorder.